The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial
Open accessAbstract
Background Microalbuminuria is an early sign of kidney disease in people with diabetes and indicates increased risk of cardiovascular disease. We tested whether a urinary proteomic risk classifier (CKD273) score was associated with development of microalbuminuria and whether progression to microalbuminuria could be prevented with the mineralocorticoid receptor antagonist spironolactone. Methods In this multicentre, prospective, observational study with embedded randomised controlled trial (PRIORITY), we recruited people with type 2 diabetes, normal urinary albumin excretion, and preserved renal function from 15 specialist centres in ten European countries. All participants (observational cohort) were tested with the CKD273 classifier and classified as high risk (CKD273 classifier score >0·154) or low risk (≤0·154). Participants who were classified as high risk were entered into a randomised controlled trial and randomly assigned (1:1), by use of an interactive web-response system, to receive spironolactone 25 mg once daily or matched placebo (trial cohort). The primary endpoint was development of confirmed microalbuminuria in all individuals with available data (observational cohort). Secondary endpoints included reduction in incidence of microalbuminuria with spironolactone (trial cohort, intention-to-treat population) and association between CKD273 risk score and measures of impaired renal function based on estimated glomerular filtration rate (eGFR; observational cohort). Adverse events (particularly gynaecomastia and hyperkalaemia) and serious adverse events were recorded for the intention-to-treat population (trial cohort). This study is registered with the EU Clinical Trials Register (EudraCT 20120-004523-4) and ClinicalTrials.gov (NCT02040441) and is completed. Findings Between March 25, 2014, and Sept 30, 2018, we enrolled and followed-up 1775 participants (observational cohort), 1559 (88%) of 1775 participants had a low-risk urinary proteomic pattern and 216 (12%) had a high-risk pattern, of whom 209 were included in the trial cohort and assigned to spironolactone (n=102) or placebo (n=107). The overall median follow-up time was 2·51 years (IQR 2·0–3·0). Progression to microalbuminuria was seen in 61 (28%) of 216 high-risk participants and 139 (9%) of 1559 low-risk participants (hazard ratio [HR] 2·48, 95% CI 1·80–3·42; p<0·0001, after adjustment for baseline variables of age, sex, HbA 1c , systolic blood pressure, retinopathy, urine albumin-to-creatinine ratio [UACR], and eGFR). Development of impaired renal function (eGFR <60 mL/min per 1·73 m 2 ) was seen in 48 (26%) of 184 high-risk participants and 119 (8%) of 1423 low-risk participants (HR 3·50; 95% CI 2·50–4·90, after adjustment for baseline variables). A 30% decrease in eGFR from baseline (post-hoc endpoint) was seen in 42 (19%) of 216 high-risk participants and 62 (4%) of 1559 low-risk participants (HR 5·15, 95% CI 3·41–7·76; p<0·0001, after adjustment for basline eGFR and UACR). In the intention-to-treat trial cohort, development of microalbuminuria was seen in 35 (33%) of 107 in the placebo group and 26 (25%) of 102 in the spironolactone group (HR 0·81, 95% CI 0·49–1·34; p=0·41). In the safety analysis (intention-to-treat trial cohort), events of plasma potassium concentrations of more than 5·5 mmol/L were seen in 13 (13%) of 102 participants in the spironolactone group and four (4%) of 107 participants in the placebo group, and gynaecomastia was seen in three (3%) participants in the spironolactone group and none in the placebo group. One patient died in the placebo group due to a cardiac event (considered possibly related to study drug) and one patient died in the spironolactone group due to cancer, deemed unrelated to study drug. Interpretation In people with type 2 diabetes and normoalbuminuria, a high-risk score from the urinary proteomic classifier CKD273 was associated with an increased risk of progression to microalbuminuria over a median of 2·5 years, independent of clinical characteristics. However, spironolactone did not prevent progression to microalbuminuria in high-risk patients. Funding European Union Seventh Framework Programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
Changes in diabetes-related complications in the United States, 1990-2010
Gregg, E. W., Li, Y., Wang, J., Rios Burrows, N., Ali, M. K., Rolka, D., Williams, D. E., & Geiss, L. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310799 · Cited by 1,749
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
Haller, H., Ito, S., Izzo, J. L., Januszewicz, A., Katayama, S., Menne, J., Mimran, A., Rabelink, T. J., Ritz, E., Ruilope, L. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007994 · Cited by 792
Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708
Self-citationGæde, P., Oellgaard, J., Carstensen, B., Rossing, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2016) · Diabetologia · doi:10.1007/s00125-016-4065-6 · Cited by 528
Self-citationNaturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease
Good, D. M., Zürbig, P., Argilés, À., Bauer, H. W., Behrens, G., Coon, J. J., Dakna, M., Decramer, S., Delles, C., Dominiczak, A. F., et al. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.001917 · Cited by 524
Self-citationHeerspink, H. J. L., Greene, T., Tighiouart, H., Gansevoort, R. T., Coresh, J., Simon, A. L., Chan, T. M., Hou, F. F., Lewis, J. B., Locatelli, F., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30314-0 · Cited by 397
Self-citationMehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L., & Toto, R. D. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070737 · Cited by 388
Cited by
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
Molecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 668
Trajectories of kidney function in diabetes: a clinicopathological update
Oshima, M., Shimizu, M., Yamanouchi, M., Toyama, T., Hara, A., Furuichi, K., & Wada, T. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00462-y · Cited by 346
Molecular pathways that drive diabetic kidney disease
Mohandes, S., Doke, T., Hu, H., Mukhi, D., Dhillon, P., & Susztak, K. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165654 · Cited by 341
Nakayasu, E. S., Gritsenko, M., Piehowski, P. D., Gao, Y., Orton, D. J., Schepmoes, A. A., Fillmore, T. L., Frohnert, B. I., Rewers, M., Krischer, J. P., et al. (2021) · Nature Protocols · doi:10.1038/s41596-021-00566-6 · Cited by 275
Metadata
- Authors
- Tofte, N., Lindhardt, M., Adamova, K., Bakker, S. J. L., Beige, J., Beulens, J. W. J., Birkenfeld, A. L., Currie, G., Delles, C., Dimos, I., Francová, L., Frimodt-Møller, M., Girman, P., Göke, R., Havrdova, T., Heerspink, H. J. L., Kooy, A., Laverman, G. D., Mischak, H., Navis, G., Nijpels, G., Noutsou, M., Ortiz, A., Parvanova, A., Persson, F., Petrie, J. R., Ruggenenti, P. L., Rutters, F., Rychlík, I., Siwy, J., Spasovski, G., Speeckaert, M., Trillini, M., Zürbig, P., von der Leyen, H., Rossing, P., Zimmermann, S., Rädisch, B., Hävemeier, A., Busmann, A., Wittkop, U., Neuhaus, B., Ax-Smolarski, R., Zieglschmid, V., Bollweber, E., Wölk, H., Curovic, V. R., Tougaard, N. H., Eickhoff, M. K., Pilemann-Lyberg, S., Winther, S. A., Rosenlund, S. V., Hansen, T. W., von Scholten, B. J., Hansen, C. S., Zobel, E. H., Laursen, J. C., Theilade, S., Jelstrup, L., Juhl, T. R., Riis, D., Hermann, J. A., Lundgaard, A. G., Halkjær, M. L. D., Aabo, L., Frost Lerche, T., Lajer, M., Stefansen, R. J., Campbell, M. A., Durban, A., Raad, J., Prigge, M., Schiemann, M., Wilson, R., Kean, S., Douglas, E., Surtees, P., Gant, C., Yeung, S. M. H., Hagedoorn, I., Flynn, J., Galloway, J., Brooksbank, K., Aparicio, C., Iliev, I. P., Nones, F., Lo Bue, F., Melacini, D., Cugini, D., Prandini, S., Lecchi, V., Yakymchuk, S., Gherardi, G., Villa, A., Villa, D., Gaspari, F., Cannata, A. N., Ferrari, S., Stucchi, N., Albrechtová, Š., Eldeik, E., Amanaki, R., Fernandez-Fernandez, B., Sanchez-Rodriguez, J., Vázquez, C., Sanz, A. B., Sanchez-Niño, M. D., Ramos, A. M., Gonzalo, M. Á., Schmidt, U., Selim, G., Gjorgovski, T., Stratrova, S. S., Stojceva-Taneva, O., Schutten-Westerneng, P., Wierbos, B., Huvers, F., De Bruin, A. K., Lapauw, B., de Man, E., Rokegem, K., Inion, S., Kreutzmann, K., Dewettinck, I., Boukens-de Graaf, C., Clerc-de Jong, F., Entius, J., Nannings, M., van Steenderen, S., Petry, F. W., & Kilic, C.
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 8
- Issue
- 4
- Pages
- 301-312
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W3009723587
- Cited by
- 262
- References
- 31
- FWCI
- 22.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s2213-8587(20)30026-7
- The paper
- Tofte, N., Lindhardt, M., Adamova, K., Bakker, S. J. L., Beige, J., Beulens, J. W. J., Birkenfeld, A. L., Currie, G., Delles, C., Dimos, I., Francová, L., Frimodt-Møller, M., Girman, P., Göke, R., Havrdova, T., Heerspink, H. J. L., Kooy, A., Laverman, G. D., Mischak, H., . . . Kilic, C. (2020). Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(20)30026-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.